Daiichi Sankyo Unveils First Clinical Data of Sixth DXd ADC DS-3939, Showing Tumor Shrinkage in Over 81% of Evaluable Patients
Daiichi-Sankyo
Pharmaceutical R&D Developer
On October 13 local time, the main body of regular abstracts for the 2025 ESMO Annual Meeting was重磅 released. At this conference, Daiichi Sankyo showcased through a short oral presentation.DS-3939 The FirstPreliminary Results of Phase I/II Human Trials.
Screenshot source: ESMO official website
DS-3939 is the first Daiichi-Sankyo-basedDXdAn ADC targeting TA-MUC1 developed by the ADC technology platform, its structure consists of a humanized anti-TA-MUC1 antibody, an enzymatically cleavable tetrapeptide linker, and a high drug-to-antibody ratio.（DAR）DNA Topoisomerase I Inhibitor（DXd）Composition.
Currently, the DXd ADC portfolio includes trastuzumab deruxtecan.（HER2 ADC）、Dedabotumab（TROP2 ADC）、Patritumab deruxtecan（HER3 ADC）、Ifinatamab deruxtecan（B7-H3 ADC）、Raludotatug deruxtecan（CDH6 ADC）AndDS-3939。DS-3939 is the sixth DXd ADC in Daiichi Sankyo's clinical development pipeline.。
The phase I/II clinical study of this drug, which was first initiated by Daiichi Sankyo in May 2023, was announced at this conference.（NCT05875168）. This study includesGlobal Dose Escalation(Part 1)And Expansion(Part 2)Part,TargetingPreviously treated, advanced solid tumor patients resistant to standard therapyPatients receive DS-3939 intravenously every 3 weeks. The primary objectives are to assess safety/tolerability and ORR.
Data as of February 28, 2025, included a total of 47 patients, including 5 with biliary tract cancer, 5 with breast cancer, 16 with NSCLC, 8 with ovarian cancer, 8 with pancreatic cancer, and 5 with urothelial cancer.
In terms of efficacy,Patients who received 2-6 doses of DS-3939 treatment and had undergone ≥1 tumor assessment post-baseline.Of 38 patients, 31 showed tumor shrinkage.（81.6%）, including 10 patients according to RECIST 1.1,（NSCLC, OC, and BC)Confirmed partial response in some patients, 23 with stable disease, and 5 with disease progression.
The most common adverse events occurring during treatment（TEAE）For nausea, vomiting, constipation, anemia, and fatigue. Other results are shown in the table.
Screenshot source: ESMO official website
Cover Source:Company Logo
Disclaimer:This article is for information sharing only,不代表 Insight 立场和观点, and does not recommend or introduce any treatment options. If you have any needs, please consult and contact正规医疗机构.
Editor: ccai
PR Article Collaboration: WeChat insightxb